Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 8,057,468 entitled "Method to Generate a Plasma Stream for Performing Electrosurgery" to Bovie Medical Corporation. The patent covers a method of performing endoscopic or laparoscopic surgery with an electrosurgical device that generates a plasma stream. The plasma stream conducts electrosurgical energy to a patient to cut and coagulate blood or tissue. The method covered by the patent provides an electronegative gas, which confines the plasma stream to an elongated narrow beam to achieve precision point accuracy and stability of the plasma stream during an electrosurgical procedure. The newly issued patent is the fourth related to Bovie’s J-Plasma technology with three additional patent applications pending. Cautionary Note on Forward-Looking Statements Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2010. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.